NEW YORK, March 5, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Analysts Review released its analysts' notes regarding
NuVasive, Inc. (NASDAQ: NUVA), IPC The Hospitalist Company, Inc.
(NASDAQ: IPCM), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), ICU
Medical, Inc. (NASDAQ: ICUI), and Prothena Corporation PLC (NASDAQ:
PRTA). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
NuVasive, Inc. Analyst Notes
On March 3, 2014, NuVasive, Inc.
(NuVasive) reported Q4 2013 and full year 2013 financial results.
During the quarter, the Company's revenue came in at $190.8 million, up 15.1% YoY, while full year
total revenue of $685.2 million was
up 10.5% YoY. Q4 2013 net income attributable to NuVasive was
$6.0 million, or $0.13 per diluted share, compared to a net loss
of $2.7 million, or $0.06 loss per diluted share, in Q4 2012.
Full-year 2013 net income attributable to the Company was
$7.9 million, or $0.17 per diluted share, compared to $3.1 million, or $0.07 per diluted share, in full year 2012. "2013
results clearly demonstrate that NuVasive's market share taking
strategy is thriving. Importantly, we are cultivating the drivers
that will support top and bottom line growth for many years to
come. We are leveraging our unrivaled years of experience and
research to continue championing the global market conversion
toward less invasive spine solutions. And our commitment to
innovation has conceived a pipeline that may dwarf all that we have
accomplished so far," said Alex
Lukianov, Chairman and CEO of NuVasive. The full analyst
notes on NuVasive, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03052014/NUVA/report.pdf
--
IPC The Hospitalist Company, Inc.
Analyst Notes
On March 3, 2014, IPC The
Hospitalist Company, Inc. (IPC) announced the appointment of
John H. Cassin to the position of
Executive Director for the Company's Colorado region. Under the new role, Cassin
will be responsible for the operational supervision of IPC's
Colorado regional services for
both acute and post-acute care business, as well as for delivering
on the Company's ongoing commitment to align its clinicians with
the operational goals of client facilities and payers. According to
IPC, Cassin will report directly to Glenn
Appelbaum, the Company's Senior Vice President for
Operations. Prior to joining the Company, Cassin served as Regional
Vice President of Operations at Sound Physicians. The full analyst
notes on IPC The Hospitalist Company, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03052014/IPCM/report.pdf
--
Portola Pharmaceuticals, Inc. Analyst
Notes
On February 27, 2014, Portola
Pharmaceuticals, Inc. (Portola)
reported Q4 2013 and full-year 2013 financial results. In Q4 2013,
the Company's collaboration and license revenue grew 5.1% YoY to
$2.1 million, while full year 2013
collaboration and license revenue of $10.5
million was down 85.4% YoY. Q4 2013 net loss stood at
$25.1 million, or $0.63 loss per diluted share, compared to a net
loss of $13.8 million, or
$10.02 loss per diluted share, in Q4
2012. Full year 2013 net loss was $83.4
million, compared to net income of $11.4 million in full year 2012. "We have a clear
strategy focused on biomarker or genetic approaches to clinical
development that we believe will increase the probability of
clinical, regulatory and commercial success of our late-stage
pipeline. Additionally, we believe we currently have sufficient
capital to independently advance our three late-stage proprietary
assets to value-creating clinical and manufacturing milestones
through 2015," said William Lis, CEO
of Portola. The full analyst notes
on Portola Pharmaceuticals, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03052014/PTLA/report.pdf
--
ICU Medical, Inc. Analyst Notes
On March 3, 2014, ICU Medical,
Inc. (ICU) announced that it will be participating at the
26th Annual ROTH Conference to be held from March 9 to March 12, 2014 at the Ritz-Carlton
Hotel in Laguna Niguel,
California. According to ICU, its CEO Scott Lamb is scheduled to present on
March 10, 2014 at 12:30 p.m. PT. The presentation will be webcast
live and can be accessed by going to the Company's website. The
full analyst notes on ICU Medical, Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03052014/ICUI/report.pdf
--
Prothena Corporation PLC Analyst
Notes
On March 3, 2014, Prothena
Corporation PLC (Prothena) announced the promotion of Tara Nickerson, PhD, MBA, to the position of
Chief Business Officer. Under the position, Dr. Nickerson will be
responsible for leading corporate and business development, as well
as alliance management efforts of the Company. Prior to the
promotion, Dr. Nickerson served as Prothena's Head of Corporate and
Business Development. Commenting on the promotion, Dr. Dale Schenk, President and CEO of Prothena said,
"Tara has brought significant business and biotechnology expertise
to Prothena since our inception. As our Chief Business Officer, she
can provide critical leadership to advance our research and
clinical pipeline." The full analyst notes on Prothena Corporation
PLC are available to download free of charge at:
http://www.AnalystsReview.com/03052014/PRTA/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review